UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of August 2025 (Report No. 2)
Commission
file number: 001-39957
NLS
PHARMACEUTICS LTD.
(Translation
of registrant’s name into English)
The
Circle 6
8058
Zurich, Switzerland
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
CONTENTS
On
August 21, 2025, the board of directors of NLS Pharmaceutics
Ltd. (the “Company”) rescheduled the meeting date of the Extraordinary Shareholders’ Meeting to approve the transactions
relating to its contemplated transaction with Kadimastem Ltd. (“Kadimastem”), which was originally scheduled to take place
on August 25, 2025, or the Meeting. This postponement is intended to allow additional time for the Company to receive and evaluate further
comments from the U.S. Securities and Exchange Commission (“SEC”) on the Company’s pending registration statement on
Form F-4 relating to the proposed merger transaction with Kadimastem, and to ensure that shareholders have access to the most current
and complete information in considering the matters to be presented at the Meeting. The Meeting has been currently rescheduled to occur
on September 16, 2025, but may be postponed to a later date, if necessary.
If
there is a subsequent postponement, the Company intends to announce the new date, time and location of the Meeting by a subsequent Report
on Form 6-K and by notice to shareholders in accordance with applicable law. No action is required by shareholders at this time.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
NLS
Pharmaceutics Ltd. |
| |
|
|
| Date:
August 25, 2025 |
By: |
/s/
Alexander Zwyer |
| |
|
Name: |
Alexander
Zwyer |
| |
|
Title: |
Chief
Executive Officer |
2
